Zygmont Chester Stanley III 4

4 · REVELATION BIOSCIENCES, INC. · Filed Feb 5, 2026

AI-generated summary of this filing

Updated Feb 5, 2026

Revelation Biosciences CFO Chester Zygmont Sells 13,100 Shares

What Happened

Chester S. Zygmont III, CFO of Revelation Biosciences, sold 13,100 shares on Feb 4, 2026 to satisfy tax withholding obligations arising on the vesting of restricted stock awards. The weighted-average price was $1.65, for proceeds of approximately $21,615. The sale was mandatory to cover taxes and not an open-market discretionary sale.

Key Details

Transaction date: 2026-02-04; Form 4 filed: 2026-02-05 (timely filing).
Price: weighted average $1.65; shares sold in multiple transactions at prices ranging $1.63–$1.66.
Amount: 13,100 shares disposed for ~$21,615.
Transaction code: F — sale to satisfy tax withholding on vesting (mandatory; reporting person did not exercise investment discretion).
Reverse split: all share counts reflect a 1-for-4 reverse stock split effective Jan 28, 2026.
Holdings notes in filing: some shares are held by The Zygmont Family Trust and by Czeslaw Capital Fund, LLC (he is trustee/sole manager).
Shares owned after the transaction are not specified in the information provided here.

Context

This was a sell-to-cover (tax withholding) related to restricted stock vesting, not a voluntary open-market sale; such transactions are routine and reflect tax obligations rather than a directional bet on the stock.
The filing discloses the weighted-average price and a range; the reporter offered to provide exact per-trade details on request.

Form 4

Period: 2026-02-04

Chief Financial Officer

Transactions

Tax Payment
Common Stock
[F1][F2][F3][F4]
2026-02-04$1.65/sh−13,100$21,615→ 105,348 total(indirect: By Trust)

Holdings

Footnotes (5)

[F1]All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.
[F2]Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
[F5]Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.

Signature

/s/ J.P. Galda, as attorney-in-fact for Chester S Zygmont III|2026-02-05

1 file